Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference

20181001 SITC Poster VEN

Published 2 October 2018
Categorized as 2018, Invir.IO, Myvac, Press release

Transgene unveils myvac™, an individualized immunotherapy against solid tumors

20180924 MyVac EN

Published 24 September 2018
Categorized as 2018, Myvac, Press release

Transgene Presents 2018 Half-Year Results and Business Update

20180919 H1 2018 RESULTS EN

Published 19 September 2018
Categorized as 2018, Press release

Transgene Announces Upcoming Investor Meetings

20180903 PR financial agenda H2 18

Published 3 September 2018
Categorized as 2018, Press release

Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares

180820 – TG Tasly Closing EN

Published 20 August 2018
Categorized as 2018, Press release, TG1050, TG6002

Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China

180710 – TG Tasly agreement PR

Published 10 July 2018
Categorized as 2018, Press release, TG1050, TG6002

Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration

20180604 PR ASCO Pexa-vec neoadjuvant data EN

Published 4 June 2018
Categorized as 2018, Pexa-Vec, Press release

Transgene Announces Upcoming Investor Meetings

20180524 PR financial meetings Q2 18

Published 24 May 2018
Categorized as 2018, Press release

Combined General Meeting of May 23, 2018

20180523 TG AGM 2018 EN

Published 23 May 2018
Categorized as 2018, Press release

Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018

20180517 PR ASCO poster accepted EN

Published 17 May 2018
Categorized as 2018, Pexa-Vec, Press release

Posts pagination

Newer posts Page 1 … Page 24 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu